[go: up one dir, main page]

WO2018151840A3 - Méthodes et compositions de traitement de tumeurs malignes - Google Patents

Méthodes et compositions de traitement de tumeurs malignes Download PDF

Info

Publication number
WO2018151840A3
WO2018151840A3 PCT/US2018/000054 US2018000054W WO2018151840A3 WO 2018151840 A3 WO2018151840 A3 WO 2018151840A3 US 2018000054 W US2018000054 W US 2018000054W WO 2018151840 A3 WO2018151840 A3 WO 2018151840A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
mammal
methods
malignant tumors
kras
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/000054
Other languages
English (en)
Other versions
WO2018151840A2 (fr
Inventor
Wenbin Ying
Kenjirou Minomi
Jihua Liu
Li Wang
Bharat Majeti
Roger Adami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitto Denko Corp
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/434,318 external-priority patent/US10792299B2/en
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Priority to JP2018535394A priority Critical patent/JP2019508379A/ja
Publication of WO2018151840A2 publication Critical patent/WO2018151840A2/fr
Publication of WO2018151840A3 publication Critical patent/WO2018151840A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne des méthodes et des compositions permettant de prévenir, de traiter ou d'atténuer un ou plusieurs symptômes d'une tumeur maligne associée à une mutation de KRAS chez un mammifère en ayant besoin, par identification d'une cellule tumorale chez ledit mammifère, la cellule tumorale étant caractérisée par au moins : (i) une mutation du gène KRAS, et/ou (ii) un niveau d'expression aberrant de la protéine KRAS ; et administration audit mammifère d'une quantité thérapeutiquement efficace d'une composition comprenant une ou plusieurs molécules d'ARNi qui sont actives pour réduire l'expression de la GST-π.
PCT/US2018/000054 2017-02-16 2018-02-16 Méthodes et compositions de traitement de tumeurs malignes Ceased WO2018151840A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2018535394A JP2019508379A (ja) 2017-02-16 2018-02-16 悪性腫瘍に対する治療方法及び治療用組成物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/434,318 2017-02-16
US15/434,318 US10792299B2 (en) 2014-12-26 2017-02-16 Methods and compositions for treating malignant tumors associated with kras mutation

Publications (2)

Publication Number Publication Date
WO2018151840A2 WO2018151840A2 (fr) 2018-08-23
WO2018151840A3 true WO2018151840A3 (fr) 2018-10-11

Family

ID=63170424

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/000054 Ceased WO2018151840A2 (fr) 2017-02-16 2018-02-16 Méthodes et compositions de traitement de tumeurs malignes

Country Status (2)

Country Link
JP (2) JP2019508379A (fr)
WO (1) WO2018151840A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220331433A1 (en) * 2019-09-06 2022-10-20 The Regents Of The University Of California Nucleic acid-mediated delivery of therapeutics

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160186182A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Rna interference compositions and methods for malignant tumors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101346393B (zh) * 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
EP2194128B1 (fr) * 2006-05-11 2012-08-01 Alnylam Pharmaceuticals Inc. Compositions et procédés d'inhibition d'expression du gène PCSK9
ES2596584T3 (es) * 2007-07-05 2017-01-10 Arrowhead Research Corporation ARNbc para tratamiento de infecciones víricas
US20160187319A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Cell death-inducing agent, cell growth-inhibiting agent, and pharmaceutical composition for treatment of disease caused by abnormal cell growth
JP6899201B2 (ja) * 2016-06-23 2021-07-07 日東電工株式会社 細胞死誘導剤、細胞増殖抑制剤及び細胞の増殖異常に起因する疾患の治療用医薬組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160186182A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Rna interference compositions and methods for malignant tumors
US20160186183A1 (en) * 2014-12-26 2016-06-30 Nitto Denko Corporation Methods and compositions for treating malignant tumors associated with kras mutation

Also Published As

Publication number Publication date
WO2018151840A2 (fr) 2018-08-23
JP2019033741A (ja) 2019-03-07
JP2019508379A (ja) 2019-03-28

Similar Documents

Publication Publication Date Title
WO2016106404A3 (fr) Méthodes et compositions destinées à traiter les tumeurs malignes associées à une mutation de kras
NZ763275A (en) Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use
PH12020500332A1 (en) Rnai agents and compositions for inhibiting expression of apolipoprotein c-iii (apoc3)
WO2019006418A3 (fr) Vecteurs viraux adéno-associés destinés à la thérapie génique
MY206230A (en) Amyloid precursor protein (app) rnai agent compositions and methods of use thereof
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
WO2018140920A8 (fr) Compositions et méthodes d'inhibition de l'expression génique du facteur xii
WO2019067666A8 (fr) Méthodes thérapeutiques se rapportant aux inhibiteurs de hsp90
WO2018098117A8 (fr) Compositions à base d'arni ciblant le gène serpina1 et leurs méthodes d'utilisation
BR112016028641A2 (pt) ?método para tratar câncer?
EA201792103A1 (ru) Композиции и способы для ингибирования экспрессии генов hif2альфа
MX2023012048A (es) Composiciones y metodos para inhibir cetohexoquinasa (khk).
IN2014DN08199A (fr)
MX2019011506A (es) Inhibicion de cinasa 1 de punto de control (chk1) para el tratamiento de cancer.
MX394425B (es) Terapia de combinación con bromodominio e inhibidor de proteína extra terminal.
MX2021008261A (es) Agentes de rnai para inhibir la expresion de hif-2 a (epas1), composiciones de estos y metodos de uso.
Wang et al. PAK inhibition by PF-3758309 enhanced the sensitivity of multiple chemotherapeutic reagents in patient-derived pancreatic cancer cell lines
WO2018033941A3 (fr) Compositions pharmaceutiques à base d'ibrutinib
BR112018011196A2 (pt) uso de pirimido-pirimidazinonas para tratar o câncer
BR112022007010A2 (pt) Terapia gênica para doença de alzheimer
WO2019075216A8 (fr) Anticorps se liant à la plectine-1 et utilisations associées
WO2018151840A3 (fr) Méthodes et compositions de traitement de tumeurs malignes
EP4516300A3 (fr) Ciblage thérapeutique rationnel d'états de signalisation immunitaire oncogènes dans des tumeurs malignes myéloïdes par l'intermédiaire de l'enzyme de conjugaison d'ubiquitine ube2n
WO2013066485A3 (fr) Compositions et méthodes de traitement d'un cancer métastatique
WO2022115664A3 (fr) Méthodes de traitement du cancer à l'aide de polythérapies épigénétiques et d'agents de ciblage de type radioconjugués

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 2018535394

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18754969

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18754969

Country of ref document: EP

Kind code of ref document: A2